Global Cancer Biomarker Market Size By Type (Protein Biomarker, Genetic Biomarker), By Application (Diagnostics, Research), By Region, And Segment Forecasts, 2023 to 2032

The Global Cancer Biomarker Market was valued at USD 17.3 billion in 2023 and is projected to reach USD 42.5 billion by 2031, growing at a CAGR of 12.1% during the forecast period from 2023 to 2031. This growth is fueled by the rising prevalence of cancer, increasing emphasis on early diagnosis, and advancements in personalized medicine. Cancer biomarkers serve as crucial indicators for detecting and monitoring different types of cancer, guiding therapeutic decisions, and improving patient outcomes. With innovations in genomics, proteomics, and bioinformatics, the utility of cancer biomarkers in clinical applications continues to expand.

Drivers:

1. Rising Incidence of Cancer Globally:

The growing cancer burden, with millions of new cases reported annually, has heightened the demand for efficient diagnostic and prognostic tools. Biomarkers play a pivotal role in early detection, which is critical for improving survival rates.

2. Advancements in Omics Technologies:

Breakthroughs in genomics and proteomics are enabling the identification of novel cancer biomarkers, enhancing accuracy in diagnosis and supporting the development of targeted therapies.

3. Increasing Investments in Cancer Research:

Public and private funding for oncology research continues to increase, propelling the discovery of biomarker-based diagnostics and treatments.

Restraints:

1. High Cost of Biomarker-based Tests and Therapies:

The development and implementation of biomarker diagnostics involve substantial R&D and operational costs, which can limit accessibility, particularly in low- and middle-income countries.

2. Regulatory and Validation Challenges:

Cancer biomarkers require rigorous clinical validation and regulatory approval, which can delay product launches and restrict market expansion.

Opportunity:

1. Integration with AI and Big Data Analytics:

The integration of artificial intelligence and machine learning with cancer biomarker research is opening new frontiers for predictive analytics and personalized treatment plans.

2. Growth in Liquid Biopsy Applications:

Non-invasive testing methods like liquid biopsies are gaining momentum, providing opportunities for biomarker detection with minimal patient discomfort.

3. Expansion in Emerging Markets:

Rising healthcare expenditure and increasing awareness in regions like Asia-Pacific and Latin America are creating lucrative opportunities for cancer biomarker adoption.

Market by System Type Insights:

In 2023, the Genomic Biomarkers segment held the largest market share. This dominance is attributed to the growing application of genomic profiling in identifying mutations and guiding targeted therapies. The segment is expected to continue its lead, driven by advancements in next-generation sequencing (NGS) technologies. However, Proteomic Biomarkers are also gaining traction for their potential in early detection and disease monitoring.

Market by End-use Insights:

The Hospitals and Clinics segment accounted for the largest market share in 2023, owing to the widespread use of biomarker-based diagnostics in oncology departments. The Research & Academic Institutions segment is anticipated to grow significantly, supported by increasing research activities in cancer genomics and drug development.

Market by Regional Insights:

North America dominated the global cancer biomarker market in 2023, driven by advanced healthcare infrastructure, high awareness levels, and strong R&D investments. Asia-Pacific is projected to witness the fastest growth during the forecast period due to rising cancer incidence, improved healthcare access, and government initiatives promoting cancer screening.

Competitive Scenario:

Key players operating in the global cancer biomarker market include Roche Diagnostics, Thermo Fisher Scientific, Abbott Laboratories, Bio-Rad Laboratories, Illumina, Inc., QIAGEN N.V., Becton Dickinson & Company, Siemens Healthineers, Agilent Technologies, and Merck KGaA. These companies are focusing on strategic partnerships, product innovation, and global expansion.

In 2023, Thermo Fisher Scientific launched a new genomic biomarker panel optimized for liquid biopsy samples.

Roche Diagnostics received regulatory approval in 2024 for its AI-integrated biomarker assay designed to enhance precision oncology.

Illumina collaborated with major cancer centers in Asia in 2025 to promote early detection initiatives through biomarker-based screening programs.

Scope of Work – Global Cancer Biomarker Market

Report Metric Details

Market Size (2023) USD 17.3 billion

Projected Market Size (2031) USD 42.5 billion

CAGR (2023–2031) 12.1%

Market Segments By System Type (Genomic, Proteomic, Epigenetic), By End-use (Hospitals, Research Institutes, Diagnostic Labs), By Region

Growth Drivers Rising cancer incidence, advances in omics technologies, growing demand for early diagnosis

Opportunities AI integration, liquid biopsy expansion, emerging market adoption

Key Market Developments:

January 2023: Roche Diagnostics introduced a companion diagnostic test based on a novel protein biomarker for lung cancer.

July 2024: QIAGEN launched a customizable gene panel for early breast cancer screening in collaboration with leading oncology centers.

February 2025: Bio-Rad Laboratories partnered with a biotech startup to commercialize a point-of-care biomarker assay for colorectal cancer.

FAQs:

1) What is the current market size of the Global Cancer Biomarker Market?

The market was valued at USD 17.3 billion in 2023.

2) What is the major growth driver